Leadership & Pay ·
Sandra Calvin, the chief accounting officer and principal accounting officer, announced her intention to retire in…
TVTXTravere Therapeutics, Inc.
Sandra Calvin, the chief accounting officer and principal accounting officer, announced her intention to retire in February 2027 following the filing of the company's Annual Report on Form 10-K. John Torell, the current Vice President and Controller, is expected to succeed her in those roles to ensure an orderly transition. Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases.